Avalyn Pharma Inc. Common Stock (AVLN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Avalyn Pharma Inc. Common Stock (AVLN) has a cash flow conversion efficiency ratio of -0.065x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-26.08 Million) by net assets ($398.35 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AVLN market cap for the company's overall valuation and market capitalisation.
Avalyn Pharma Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Avalyn Pharma Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View AVLN stock price and chart for real-time trading data and today's change.
Avalyn Pharma Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avalyn Pharma Inc. Common Stock ranked by their cash flow conversion efficiency. Review AVLN financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
G-III Apparel Group Ltd
NASDAQ:GIII
|
0.129x |
|
Zimplats Holdings Ltd
AU:ZIM
|
-0.001x |
|
Anhui Expressway Company Limited
F:HU7
|
0.027x |
|
Yelp Inc
NYSE:YELP
|
0.179x |
|
Celltrion Pharm Inc
KQ:068760
|
0.055x |
|
Securitize Corp.
NYSE:SECZ
|
0.061x |
|
Guangdong CHJ Industry Co Ltd
SHE:002345
|
-0.164x |
|
Nantong Jiangshan Agrochemical & Chemicals Co Ltd
SHG:600389
|
0.047x |
Annual Cash Flow Conversion Efficiency for Avalyn Pharma Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Avalyn Pharma Inc. Common Stock from 2024 to 2025. Also see how large is Avalyn Pharma Inc. Common Stock's balance sheet for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-238.66 Million | $-81.48 Million | 0.341x | +23.19% |
| 2024-12-31 | $-174.52 Million | $-48.37 Million | 0.277x | -- |
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled fo… Read more